Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial

Sébastien Gaujoux; Jean-Marc Régimbeau; Guillaume Piessen; Stéphanie Truant; Frantz Foissac; Louise Barbier; Emmanuel Buc; Mustapha Adham; David Fuks; Sophie Deguelte; Fabrice Muscari; Laurent Sulpice; Jean‐Christophe Vaillant; Lilian Schwarz; António Sá Cunha; Milena Muzzolini; B. Dousset; Alain Sauvanet

doi:10.1097/sla.0000000000006313

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Pharmacological prevention of postoperative pancreatic fistula (POPF) after pancreatectomy is open to debate. The present study compares clinically significant POPF rates in patients randomized between somatostatin versus octreotide as prophylactic treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gaujoux et al. (2024) studied this question.

synapsesocial.com/papers/68e6d7feb6db643587655417 https://doi.org/10.1097/sla.0000000000006313

View at Publisher

Ask AI

Bookmark

Share

Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading